Abstract
INTRODUCTION: Observational studies suggest that angiotensin receptor blockers (ARBs) are associated with lower dementia risk than angiotensin-converting enzyme inhibitors (ACEIs). Whether dementia risk differs across individual ARBs remains uncertain and was investigated in this study.
METHODS: This retrospective cohort study emulated target trials using electronic health record and claims data from 44 US health care organizations in the TriNetX Linked Research Network. ACEI/ARB-naive adults aged 55 to 80 years initiating an ARB or lisinopril were eligible. Separate 1:1 propensity-score matching was performed for each comparison. Individual and pooled ARBs were compared with lisinopril (between-class), and non-losartan ARBs with losartan (within-class). The primary outcome was incident all-cause dementia; secondary outcomes included Alzheimer disease, vascular dementia, cerebral infarction, death, and dementia or death. Cox models estimated hazard ratios (HRs) and 95% CIs. Sensitivity analyses included lagged and treatment-persistence analyses, control outcomes, and E-values.
RESULTS: Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years. Pooled ARBs were associated with lower dementia risk than lisinopril (HR, 0.86; 95% CI, 0.85 to 0.87), with substantial variation across individual agents (HR range, 0.66 to 0.93). Within-class comparisons showed similar heterogeneity (HR range, 0.68 to 0.94) and reproduced between-class agent ordering by HR estimates. Considerable agent-level variation was also observed across secondary outcomes. Losartan, the most commonly prescribed ARB, had the least favorable dementia associations. Negative-control associations were near null within class, and sensitivity analyses supported robustness.
DISCUSSION: Individual ARBs were associated with differing dementia risks, suggesting clinically relevant within-class heterogeneity pending confirmation in randomized trials.